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SUMMARY
We investigated the prevalence of the coagulation factor V gene G1691A mutation in 64 patients with Behcet's disease (BD)
and in 107 apparently healthy individuals. The mutation was present in the heterozygous state in 37.5% of the patients with
a history of deep vein thrombosis (12/32) and in 9.4% of the patients without any thrombotic event (3/32). Eleven healthy
individuals were also heterozygous for the mutation (10.3%). The prevalence of the mutation in BD patients with and without
thrombosis was significantly different (P = 0.0079). We conclude that the factor V gene mutation may play a major role in the
development of venous thrombosis in BD.
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BEHCET'S disease (BD) is a multisystemic chronic
inflammatory disorder of unknown aetiology, with
vasculitis as the main pathological process. Although
involvement of blood vessels of all types and sizes is a
prominent feature of the disease, venous involvement
is seen more frequently (20-40%) than arterial disease
[1]. Superficial thrombophlebitis is the most frequent
form of vascular disease, followed by deep vein
thrombosis of especially the lower extremities, which
can be seen in 19% of Turkish patients [1,2].
Additionally, vascular disease is more frequent and
severe in males [1].
Although a decrease in fibrinolysis was described, a
specific molecular defect leading to thrombosis has not
been identified in patients with BD [3]. Endothelial
dysfunction resulting from immune-mediated vasculitis
is suggested as the basis of thrombotic vascular
complications [4].
Resistance to activated protein C (APQ has been
described as the most common inherited coagulation
defect associated with venous thrombosis [5]. The
molecular basis of APC resistance has recently been
shown to be a single point mutation (G1691 A) in the
coagulation factor V gene [6]. This molecular defect
was found in ~ 20-40% of patients with idiopathic
deep vein thrombosis [5, 6].
We investigated whether the presence of the factor V
gene G1691A mutation was associated with the
development of venous thrombosis in BD by this
case-control study.
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PATIENTS AND METHODS
Patients and healthy individuals
A total of 64 patients, 32 with a history of deep vein
thrombosis (T + ), and 32 age- and sex-matched
patients without any thrombotic events (T—), all
fulfilling three or more International Study Group
(ISG) criteria for BD, were included (Table I) [2]. All
T+ patients had deep vein thrombosis of the lower
extremities. In addition, 10 patients also had superficial
thrombophlebitis, and three had inferior vena cava,
two had superior vena cava and two had sagittal sinus
thromboses. Arterial involvement with aneurysm
formation, and thrombotic occlusion in pulmonary,
brachial, iliac and femoral arteries, was present in four
patients. Patients with no history of thrombosis during
a disease duration of at least 5 yr were selected as the
T— group since the vascular involvement appears to
decrease after 5 yr from the onset of the disease [1].
Frequencies of oral and genital ulcers, eye disease, skin
manifestations and a positive pathergy test were quite
similar in both groups. Arthritis was more frequent in
patients without thrombosis (24 patients in T— vs 11
patients in T + ), whereas the number of patients with
central nervous system disease was higher in the other
group (five patients in T+ vs one patient in T —).
We also screened 107 apparently healthy unrelated
subjects for estimation of the prevalence of the factor
V gene mutation in the Turkish population.
DNA analysis
The presence of the G1691A mutation in exon 10 of
the factor V gene was detected by polymerase chain
reaction as described previously [7]. Briefly, it was
demonstrated by digestion of amplified factor V DNA
with Mnll and visualization of the cleavage products
on ethidium bromide-stained agarose gels. A second
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TABLE I















Age (yr) Disease duration (yr) —
mean ± s.D. (range) mean ± s.D. (range)
36 ± 9 (20-53) 9 ± 4 (2-20)
40 ± 9 (22-63) 11 ± 6 (5-28)










•Genotype: G,A - heterozygous for the G1691A mutation; G,G - no mutation. • versus b, P •= 0.0079.
amplification and digestion was performed to confirm
the presence of the mutation.
Statistical analysis
We compared the percentages of the mutation in the
T+ and T— groups by x2 test, and calculated the odds
ratio for estimation of thrombosis risk in the presence
of the factor V gene mutation. The effects of male
dominance on the results were tested by logistic
regression.
RESULTS
The factor V gene mutation was found in 12 (10
male, 2 female) of the T+ (37.5%) and in three (two
male, one female) of the T— group (9.4%) (Table I).
All of the patients who tested positive were
heterozygous for the mutation (Fig. 1). In the T+
group, all patients with superior and inferior venae
cavae, and sagittal sinus thromboses lacked the
mutation, whereas two out of four patients with
arterial and venous involvement (in iliac and
femoral arteries) were found to be positive for the
mutation.
All BD patients carrying the mutation had a history
of oral and genital ulcerations, and skin manifesta-
tions, including the pathergy reaction. Among the T +
patients, two also had uveitis and four had recurrent
attacks of oligoarthritis. Two of the patients in the T —
group experienced one attack of acute oligoarthritis.
Although all three T - patients with the mutation
fulfilled the ISG criteria for BD, they remained
asymptomatic for years, except for rarely recurring oral
aphthous ulcerations, and had a very mild disease
course.
The mutation frequency was significantly higher in
BD patients with than without thrombosis
(P = 0.0079). Heterozygosity for the factor V gene
mutation was found to be associated with an almost
6-fold increase in the risk of venous thrombosis (odds
ratio 5.8, 95% Cl 1.4-23.2). Logistic regression
analysis revealed no significant effect of male
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FIG. 1.—A 223 base pair (bp) fragment was amplified from genomic DNA and digested with Mnl\ as described previously [7]. The products
were separated on a 2% agarose gel and stained with ethidium bromide. The fragments measuring 37, 82 and 104 bp indicate the 1691G allele,
and those of 82 and 141 bp the 1691A allele. Lanes 1, 3 and 4 show BD patients without mutation; lanes 2 and 5, BD patients heterozygous
for the mutation; and the last lane the 1 kb marker.
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In the healthy controls, we identified 11 (six male,
five female) individuals heterozygous for the mutation.
This gives an allelic frequency of ~5.1% in the
Turkish population. The healthy control group and BD
patients without thrombosis had similar mutation
frequencies.
DISCUSSION
In patients with an inherited predisposition to
thrombosis, a secondary insult such as surgery or
pregnancy is needed to trigger a thrombotic event. The
episodic nature of thrombosis, even in patients with
more than one prothrombotic mutation, indicates the
involvement of secondary factors. Endothelial micro-
environment changes in BD may act as a secondary
thrombogenic stimulus which results in thrombosis in
patients with the factor V gene mutation. However,
similar to the idiopathic deep vein thrombosis, the
factor V gene mutation can explain the pathogenesis of
thrombosis in 37.5% of our T+ patients. Therefore,
the involvement of other known or as yet unidentified
procoagulant genetic defects might be expected in the
remaining T + patients. In fact, protein C and protein
S deficiency have previously been documented in cases
of BD with extensive venous thrombosis [8, 9].
Male dominance in the T + patients is consistent
with previous reports [1, 2]. Since male sex and younger
age of onset are associated with more severe disease in
BD [10, 11], a higher prevalence of venous thrombosis
could be explained by the severity of inflammation that
might affect the extent of the endothelial dysfunction
and cause a stronger thrombogenic insult. The absence
of thrombosis in three patients with the mutation in the
T— group might be due to their very mild disease
course.
No factor V gene mutation could be shown in 12 BD
patients with venous thrombosis in a recently published
letter. Although ethnic diversity might have con-
tributed to this contradictory finding, the small number
in the study group prevents any conclusions being
reached [12].
CONCLUSION
In conclusion, molecular defects of the coagulation
system may play a major role in the development of
venous thrombosis in BD. The factor V gene mutation
appears to account for almost 38% of these genetic
defects and is associated with a 6-fold increase in the
risk of venous thrombosis in BD. Demonstration of
this mutation at the time of diagnosis can identify those
patients with BD who have a high risk of deep vein
thrombosis.
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